Prof. Dr. Axel Schambach
Axel Schambach is a Principal Investigator in SP7 and a member of the Selection Committee.
His research focus lies on disease modeling and tailored therapy as well as gene and cell therapy in molecular medicine, especially molecular oncology.
Professor Schambach has served in a wide variety of roles in the research system, including as president of the German Society for Gene Therapy (since 2023), EU-/ERC-Representative for the MHH Senate (since 2021), Vice Chairman of the PhD Program Molecular Medicine (since 2020), and member of the Research Committee of the MHH (since 2020).
| Year | Position |
|---|---|
| Since 2017 | Director, Institute of Experimental Hematology, MHH |
| 2013-2017 | Acting Director, Institute of Experimental Hematology, MHH |
| 2013-now | W3 Professor for Genetic Modification of Somatic Cells, MHH |
| 2012-now | Adjunct Faculty and Lecturer, Division of Hematology / Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, USA |
| 2012-2019 | Group Leader RGs Regenerative Gene Therapy und Enhanced & Synthetic Cells for Regeneration, REBIRTH Cluster of Excellence, MHH |
| 2009-2014 | Junior Group Leader, JRG Modern Applications in Biotechnology, Gene therapy, supported by DAAD and BMBF |
| 2007-2012 | Junior Group Leader, JRG Hematopoietic Cell Therapy, REBIRTH Cluster of Excellence, MHH |
| 2005 | PhD (“summa cum laude”), Hannover Medical School (Supervisor: Prof. Christopher Baum) |
| 2002-2006 | Scientist, Experimental Cell Therapy / Institute of Experimental Hematology, MHH |
| 2003 | Dr. med. (“summa cum laude”), Hamburg University (Supervisors: Prof. Hans-Georg Kräusslich, Prof. Christopher Baum) |
| 2002-2003 | Resident doctor, Children’s Hospital, MHH |
| 1995-2001 | Studies of Human Medicine, Hamburg University |